Drug Profile
Research programme: tissue factor pathway inhibitors - Affymax/EntreMed
Latest Information Update: 27 Aug 2009
Price :
$50
*
At a glance
- Originator EntreMed
- Developer Affymax; EntreMed
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Thromboplastin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer